In 2015, C4 therapeutics were established to advance TPD technologies for cancer treatment.73 Since then, PROTAC development has increased, with degraders targeting critical proteins such as PI3K, ALK, and AR via E3 ligases such as CRBN, Von Hippel-Lindau (VHL), IAP, and MDM2.77,78 In 2018, the field of TPD achieved a pivotal milestone with the initiation of clinical trials for ARV-110, the first-in-class AR degrader. This evidence concerns the gene AR and cancer.